Market News

Global Collagen Filler Market – Drivers

Increasing launch of new products in collagen fillers

Increasing launch of new products in collagen fillers is expected to drive the global collagen filler market growth over the forecast period. For instance, in September 2022, the U.S. Food and Drug Administration approved Daxxify, manufactured by Revance Aesthetics, a U.S.- based aesthetics company. It is a new drug that may reduce the appearance of facial wrinkles for about six months, and can be an alternative to Botox.

Increasing launches of new technologies

Increasing launches of new technologies is expected to drive the global collagen filler market growth. For instance, according to the article published by Journal Gels, on May 23, 2022, an innovative technology for manufacturing collagen based dermal fillers was developed. This HACL-CTL (cross-linked hyaluronic acid and lactose modified chitosan) technology uses minimum amount of crosslinking agents, as these are toxic, and associated with several adverse reactions. New fillers based on collagen, functionalized with 1,4-butanediol diglycidyl ether and lactose modified chitosan were used.

Global Collagen Filler Market: Key Developments

In November 2022, LifeSprout, a U.S.-based regenerative medicine company, announced positive six-month interim results from its pivotal clinical trial of Lumina, a collagen filler. Lumina achieved its primary endpoint of correction of moderate-to-severe nasolabial folds (NLF) with good safety.

According to data published by Good clinical practice network, a multidisciplinary and multilingual platform by the World Health Organization on March 10, 2023, clinical trials are being conducted by SciVision Biotech Inc., company engaged in the manufacturing and distribution of hyaluronic acid medical supplies for evaluation of the safety and effectiveness of a novel gel-type sodium hyaluronate for the orrection of aging mid-face.

On March 4, 2021, Galderma, a Switzerland-based dermatology company, announced a European re-launch of Sculptra (injectable poly-L-lactic acid), a collagen stimulator, with an updated administration protocol. The product is ready for use more quickly following reconstitution, with increased levels of comfort for patients.

On September 23, 2021 Galderma, a Switzerland-based dermatology company, and Sofregen Medical, Inc., a U.S.-based medical device company, announced that both companies had signed a co-development and option-to-acquire agreement. This agreement will broaden Galderma's capabilities, which are founded on decades of science-based aesthetics innovation in biostimulator and hyaluronic acid (HA) fillers.

Global Collagen Filler Market: Restraints

Collagen fillers are associated with several side effects. These side effects may impact on the market growth. For instance, according to the article published by U.S. Food and Drug Administration on April 2, 2022, the collagen fillers are associated with side effects such as bruising, redness, swelling, pain, tenderness, itching, rash, and difficulty in performing activities. The most serious risk associated with these filler is accidental injection into blood vessels. Fillers that enter a blood vessel can cause skin necrosis, stroke, or even blindness.

To counterbalance this restraint, a safe procedures with minimum side effects must be developed.